A combinational cancer therapy that inhibits cancer cell signaling and metabolism.
- Inhibits two key cancer regulatory systems for a synergistic effect.
- Optimizes proposed methods of cancer treatment.
The basis for 2-deoxyglucose (2-DG) as a cancer therapeutic is centered on in vitro studies demonstrating the ability of 2-DG to inhibit glycolysis by the deletion of intracellular ATP. However, since 2-DG also activates the Akt pathway through insulin growth factor 1 (IGF1) receptor (IGF1R) signaling, a feedback loop is established that counteracts the 2-DG induced apoptotic effects. This explains why when 2-DG is administered in vivo it does not robustly induce tumor cell death. Therefore, a combination therapeutic that not only inhibits glycolysis, but also down-regulates key signaling molecules that promote cancer cell survival could have a more meaningful effect.
In hallmark studies aimed at describing novel cancer treatments, Emory University scientists have found that the co-administration of 2-DG with an IGF1R inhibitor creates a synergistic effect that decreases tumor cell proliferation and enhances cancer cell apoptosis. This approach to cancer treatment is timely and important considering 2-DG therapy is currently being clinically evaluated in India and is under consideration in the U.S. Moreover, an increasing number of studies have demonstrated the benefits of combination cancer treatments involving 2-DG. Indeed, when 2-DG is used in conjunction with radiation, carboplatin or paclitaxel enhanced cell killing occurs. Therefore, it is clear that a combination approach that involves the co-adminstration of 2-DG with IGF1R inhibitors affects both cancer cell metabolism and signaling; thus, dramatically reducing tumor size and growth.